Valneva initiates heterologous booster trial of inactivated, COVID-19 vaccine candidate

Latest Posts

VitaDX signs a strategic partnership with the XPath group for the use of its VisioCyt® software solution

8 September 2022

XPath, a group of medical specialists in pathological anatomy and cytology, a player in this medical specialty that has made... View Article

AbolerIS Pharma selected for the HealthTech For Care Innovation Award

6 September 2022

The HealthTech For Care Innovation Award will be presented for the first time at the HealthTech Innovation Days on October... View Article

Valneva reports further positive phase 3 immunogenicity and the first heterologous booster tesults for its inactivated, adjuvanted COVID-19 vaccine VLA2001

Valneva, a specialty vaccine company, reported further positive Phase 3 results for its inactivated, adjuvanted COVID-19 vaccine VLA2001. Additional readouts... View Article

« Previous 1 … 10 11 12 13 14 … 160 Next »